FB Pixel no scriptInsights | KrASIA
MENU
KrASIA

Insights

Insights

After Hengrui’s USD 500 million deal with GSK, which biotech firms are next in line?

As patent cliffs approach and new mechanisms gain ground, COPD drugs like HRS-9821 are fast becoming coveted assets.

6 mins read
  • Once the go-to for in-vehicle chips, Nvidia is facing defections from Chinese carmakers amid delays, performance setbacks, and cultural disconnect.

    Insights

    From dominance to doubt: How Nvidia fumbled its shot at powering China’s cars

    11 mins read

Most Recent

See All